Greg Sieczkiewicz
Directeur/Bestuurslid bij Solarea Bio, Inc.
Oorsprong van het eerstegraads netwerk van Greg Sieczkiewicz
| Entiteit | Type entiteit | Industrie | |
|---|---|---|---|
MPM BioImpact, Inc
 MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts.
54
| Private Company | Investment Managers | 54 |
Solarea Bio, Inc.
 Solarea Bio, Inc. BiotechnologyHealth Technology Solarea Bio, Inc. engages in the development of microbiome-based therapeutics to treat human disease. The company is headquartered in Hopkinton, MA.
5
| Holding Company | Biotechnology | 5 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Greg Sieczkiewicz via zijn persoonlijke netwerk
| Onderneming | Sector | Gelieerde personen | Hoofdpost |
|---|---|---|---|
| GILEAD SCIENCES, INC. | Biotechnology | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
| IDENIX PHARMACEUTICALS INC | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member | |
| RADIUS HEALTH, INC. | Biotechnology | Director/Board Member Director/Board Member Director/Board Member | |
| CHIASMA, INC. | Pharmaceuticals: Major | Director/Board Member Chairman Director/Board Member Chief Tech/Sci/R&D Officer | |
Clinical Ink, Inc.
 Clinical Ink, Inc. Internet Software/ServicesTechnology Services Clinical Ink, Inc. provides electronic source solutions for clinical research sites. Its solutions include data management, monitoring, clinical sites and patient centric. The company was founded by Douglas E. Pierce Jr. and Tommy Littlejohn on July 19, 2006 and is headquartered in Winston-Salem, NC. | Internet Software/Services | Director/Board Member Director/Board Member Director/Board Member | |
Potenza Therapeutics, Inc.
 Potenza Therapeutics, Inc. BiotechnologyHealth Technology Potenza Therapeutics, Inc. develops oncology programs and mechanisms for tumors detection. It is focusing on the discovery and development of novel immune-oncology therapeutics: molecules that stimulate the power of the immune system to fight cancer. The company was founded by Drew M. Pardoll and Daniel J. Hicklin in 2014 and is headquartered in Cambridge, MA. | Biotechnology | Founder Director/Board Member Chief Operating Officer | |
| NOVARTIS AG | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA. | College/University | Corporate Officer/Principal Doctorate Degree Masters Business Admin Masters Business Admin Doctorate Degree Doctorate Degree Undergraduate Degree Undergraduate Degree Doctorate Degree Doctorate Degree Doctorate Degree | |
| PACIRA BIOSCIENCES, INC. | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer Chief Tech/Sci/R&D Officer | |
The Boston Consulting Group, Inc.
 The Boston Consulting Group, Inc. Miscellaneous Commercial ServicesCommercial Services The Boston Consulting Group, Inc. engages in the provision of management consulting services. It specializes in automotive and mobility; biopharmaceuticals; consumer products; education; oil and gas; power and utilities; engineered products and infrastructure; financial institutions; and health care payers, providers, and services. It offers big data and advanced analytics; change management; client learning and enablement; and corporate development and financial services. The company was founded by Bruce Doolin Henderson in 1963 and is headquartered in Boston, MA. | Miscellaneous Commercial Services | Corporate Officer/Principal Consultant / Advisor Private Equity Investor | |
Flagship Pioneering
 Flagship Pioneering Investment ManagersFinance Flagship Pioneering (Flagship Pioneering) is a venture capital firm founded in 1982 by Ed M Kania and Noubar B Afeyan. The firm is headquartered in Cambridge, Massachusetts. | Investment Managers | Consultant / Advisor Private Equity Investor Private Equity Analyst | |
| Massachusetts Institute of Technology | College/University | Undergraduate Degree Graduate Degree Corporate Officer/Principal Graduate Degree Doctorate Degree Graduate Degree Doctorate Degree Doctorate Degree | |
| Brandeis University | College/University | Undergraduate Degree Undergraduate Degree | |
Cornell University
 Cornell University Other Consumer ServicesConsumer Services Cornell University is an educational institution that offers undergraduate and post graduate programs. It was founded in 1865 and is based in Ithaca, NY. | College/University | Undergraduate Degree Undergraduate Degree | |
| Princeton University | College/University | Undergraduate Degree Corporate Officer/Principal Doctorate Degree | |
| AVEO PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Chief Tech/Sci/R&D Officer | |
| SOLASIA PHARMA K.K. | Pharmaceuticals: Major | Chairman Director/Board Member | |
| Harvard Medical School | College/University | Doctorate Degree Doctorate Degree Doctorate Degree Graduate Degree Doctorate Degree | |
Mitobridge, Inc.
 Mitobridge, Inc. BiotechnologyHealth Technology Mitobridge, Inc. operates as a biopharmaceutical company. It focuses on the development and discovery of products for mitochondrial function. The firm also offers treatments for genetic, metabolic, and neurodegenerative disorders as well as diseases and conditions of aging. The company was founded by Kazumi Shiosaki, Andrew Dillin, Ronald M. Evans, Johan Auwerx and Robert H. Horvitz in October 2011 and is headquartered in Cambridge, MA. | Biotechnology | Director/Board Member Founder | |
Amphivena Therapeutics, Inc.
 Amphivena Therapeutics, Inc. Drugstore ChainsRetail Trade Amphivena Therapeutics, Inc. provides drug discovery services. It develops tetravalent, T-cell redirecting bispecific antibodies for the treatment of hematologic malignancies. The firm’s’ lead drug candidate is AMV-564, a CD33/CD3-targeting treatment for acute myeloid leukemia (AML), which Amphivena is currently preparing to advance into clinical development. The company was founded by Jeanmarie Guenot in December 2012 and is headquartered in San Francisco, CA. | Drugstore Chains | Founder Director/Board Member Director/Board Member Director/Board Member | |
| Harvard Business School | College/University | Masters Business Admin Masters Business Admin Masters Business Admin | |
| OSS Healthcare, Inc. | Director/Board Member Director/Board Member | ||
TriNetX, LLC
 TriNetX, LLC Medical/Nursing ServicesHealth Services TriNetX, Inc. provides an online data network for collaborative research. It enables hospitals, academic medical centers, physician networks, practices, and pharmaceuticals to participate in collaborative research and a public and private sustainability model for research informatics. The company was founded by Bard Geesaman in 2013 and is headquartered in Cambridge, MA. | Medical/Nursing Services | Director/Board Member Director/Board Member Corporate Officer/Principal Director/Board Member | |
Blade Therapeutics, Inc.
 Blade Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Blade Therapeutics, Inc. offers anti-fibrotic therapies to meet unserved patient needs. Its product portfolio is to address various fibrotic diseases and their underlying pathophysiology. The company was founded by Hal Dietz and Wendye R. Robbins and is headquartered in South San Francisco, CA. | Miscellaneous Commercial Services | Founder Chairman Chief Tech/Sci/R&D Officer Director/Board Member | |
Tizona Therapeutics, Inc.
 Tizona Therapeutics, Inc. BiotechnologyHealth Technology Tizona Therapeutics, Inc. is an immunology company harnessing the power of the immune system to develop treatments for cancer and autoimmune diseases. Its products include anti-ccr4 antibody for the treatment of cancer, il-35 antagonists for the treatment of cancer, and il-35 agonists for the treatment of autoimmune diseases. The company was founded by Charles G. Drake, Vijay K. Kuchroo, Drew M. Pardoll, Dario Vignali, Wayne A. Marasco and Jedd D. Wolchok and is headquartered in South San Francisco, CA. | Biotechnology | Founder Chief Executive Officer Director/Board Member Director/Board Member | |
| HARPOON THERAPEUTICS, INC. | Biotechnology | Founder Director/Board Member Founder | |
| ONCORUS, INC. | Biotechnology | Chairman Chief Executive Officer Director/Board Member | |
iOmx Therapeutics AG
 iOmx Therapeutics AG BiotechnologyHealth Technology iOmx Therapeutics AG develops immunotherapy treatments for cancer patients. It specializes in immuno oncology, drug development and cancer therapy. The company was founded by Nisit Khandelwal, Philipp Beckhove, Patrick Baeuerle, Sebastian Meier-Ewert and Elmar Maier in March 2016 and is headquartered in Munich, Germany. | Biotechnology | Director/Board Member Founder Director/Board Member | |
| TCR2 THERAPEUTICS INC. | Pharmaceuticals: Major | Chairman Director/Board Member Founder | |
KSQ Therapeutics, Inc.
 KSQ Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology KSQ Therapeutics, Inc. develops and deploys precision functional genomics to discover therapies that transform patient lives. The company was founded by Tim Wang and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Director/Board Member Founder | |
Maverick Therapeutics, Inc.
 Maverick Therapeutics, Inc. BiotechnologyHealth Technology Maverick Therapeutics, Inc. operates as a preclinical stage biotech company. It develops a novel class of T cell- redirecting antibody therapeutics that have the potential to substantially broaden the range of targets and clinical applications to be used for this ultra-potent mechanism. The company was founded by Robert Dubridge and Patrick A. Baeuerle in 2016 and is headquartered in Brisbane, CA. | Biotechnology | Founder Founder Director/Board Member | |
| ALLOVIR, INC. | Biotechnology | Director/Board Member Chief Tech/Sci/R&D Officer Chief Executive Officer | |
CODA Biotherapeutics, Inc.
 CODA Biotherapeutics, Inc. Medical SpecialtiesHealth Technology CODA Biotherapeutics, Inc. engages in the development of chemo genetic neuromodulation platform for the treatment of severe neurological disorders. The company was founded by Mitchell H. Finer, Allan Basbaum, Nicholas Boulis, Joseph Glorioso III and Kenneth P. Greenberg in 2014 and is headquartered in South San Francisco, CA. | Medical Specialties | Director/Board Member Director/Board Member Founder | |
Rekindle Therapeutics, Inc.
 Rekindle Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Rekindle Therapeutics, Inc. operates as an biotechnology company. The company is headquartered in Cambridge, MA. | Miscellaneous Commercial Services | Chairman Chief Executive Officer | |
Biointervene, Inc.
 Biointervene, Inc. Pharmaceuticals: MajorHealth Technology Biointervene, Inc. operates as a biopharmaceutical company. The company was founded by Gary J. Bennett and Daniela Salvemini in 2014 and is headquartered in San Diego, CA. | Pharmaceuticals: Major | Chairman Chief Tech/Sci/R&D Officer | |
ElevateBio LLC
 ElevateBio LLC BiotechnologyHealth Technology ElevateBio LLC is a biotechnology holding company, which creates and operates a broad portfolio of cell and gene therapy companies. It builds single and multi-product companies by providing scientific founders with bench-to-bedside capabilities including scientists, manufacturing facilities, drug developers, and commercial expertise. The company was founded by David L. Hallal, Vikas Sinha, and Mitchell H. Finer and is headquartered in Cambridge, MA. | Biotechnology | Director/Board Member Founder | |
| WEREWOLF THERAPEUTICS, INC. | Pharmaceuticals: Major | Founder Founder Director/Board Member Chief Operating Officer Chief Operating Officer | |
| ITEOS THERAPEUTICS, INC. | Biotechnology | Director/Board Member Director/Board Member Director/Board Member | |
Nextpoint Therapeutics, Inc.
 Nextpoint Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Nextpoint Therapeutics, Inc. is a biotech company based in Cambridge, MA. The company is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. The company's innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Nextpoint Therapeutics has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class immunotherapies. Detlev Biniszkiewicz has been the CEO of the company since 2018. | Miscellaneous Commercial Services | Chairman Director/Board Member Chairman Director/Board Member Director/Board Member | |
Orna Therapeutics, Inc.
 Orna Therapeutics, Inc. BiotechnologyHealth Technology Orna Therapeutics, Inc. is a biotechnology company that designs and delivers fully engineered circular RNA therapeutics to treat diseases. Orna Therapeutics is based in Cambridge, MA, and has subsidiaries in the United States. The company's proprietary platform combines novel technology to create RNA that drives protein expression with validated and unique delivery solutions. Orna has many advantages over traditional approaches, including simplified production, improved formulatability, and superior protein expression. The company was founded by Daniel Anderson, Raffaella Squilloni, Alex Wesselhoeft, and the CEO is Thomas M. Barnes. | Biotechnology | Chairman Director/Board Member Director/Board Member Chief Executive Officer Director/Board Member | |
| TURMERIC ACQUISITION CORP. | Financial Conglomerates | Chief Executive Officer Director/Board Member Director of Finance/CFO President Director/Board Member Chairman Chief Operating Officer | |
| CULLINAN THERAPEUTICS, INC. | Pharmaceuticals: Major | Chairman Director/Board Member Director/Board Member Founder Director of Finance/CFO Corporate Officer/Principal Director/Board Member | |
Aktis Oncology, Inc.
 Aktis Oncology, Inc. Medical/Nursing ServicesHealth Services Aktis Oncology, Inc. is a biotechnology company located in Boston, MA. The company specializes in the discovery and development of a new class of targeted alpha radiopharmaceuticals to treat a broad range of solid tumor cancers. The company's molecules are designed for high tumor penetration and long residence time, which maximizes tumor elimination while minimizing side effects of treatment. The approach enables clinicians to visualize and verify target engagement prior to exposure to therapeutic radioisotopes. Founded and incubated by MPM Capital, Aktis Oncology has developed proprietary platforms to generate tumor targeting agents with ideal properties for alpha radiotherapy. Matt M. Roden has been the CEO of the company since 2020. | Medical/Nursing Services | Chairman Chief Executive Officer Corporate Officer/Principal | |
Bioimpact Capital LLC
 Bioimpact Capital LLC Investment ManagersFinance MPM BioImpact LLC (MPM BioImpact) is a venture capital firm a subsidiary of MPM Bioimpact Inc founded in 1996. The firm is headquartered in Cambridge, Massachusetts. | Investment Managers | Private Equity Investor Private Equity Investor Consultant / Advisor Director of Finance/CFO Private Equity Investor Private Equity Investor Private Equity Investor Consultant / Advisor Private Equity Investor Private Equity Investor Private Equity Investor Director/Board Member | |
Crossbow Therapeutics, Inc.
 Crossbow Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Crossbow Therapeutics, Inc. is a biotechnology company that aims to improve the lives of people with cancer by developing next-generation immunotherapies. The company is based in Cambridge, MA, and the CEO of the company is Briggs W. Morrison. The company's T-bolt™ therapies are designed to target previously unreachable cancer cell targets with high precision. Crossbow's approach is efficient and selective, allowing them to target the entire universe of cancer proteins, which expands the potential of antibody therapy to address many types of cancer. | Pharmaceuticals: Major | Director/Board Member Chief Tech/Sci/R&D Officer Chief Executive Officer | |
Renagade Therapeutics, Inc.
 Renagade Therapeutics, Inc. BiotechnologyHealth Technology Renagade Therapeutics, Inc. is an American US-based company that aims to overcome the limitations of RNA medicines by applying their comprehensive deliver, code, edit, insert technologies to precisely correct disease on an unprecedented scale. The company has developed a broad portfolio of RNA delivery systems, which profoundly expand the array of addressable diseases. The company's proprietary, synergistic toolkit allows them to precisely deliver, code, edit, and insert RNA medicines to treat any disease, anywhere in the body. Renagade is built on a foundation of proprietary delivery technologies to unlock previously inaccessible cells, reprogramming cells with superior expression using the leading RNA coding platform via joint venture with Orna Therapeutics, enabling curative therapies by permanently correcting defective genes with proprietary technology, and industry-leading all-RNA system to enable exon or large gene insertions as a gene therapy 2.0 platform. Renagade is backed by MPM BioImpact and F2 Ventures, leading financial groups who have supported the development of over 50 products to market. | Biotechnology | Founder Director/Board Member Founder | |
Semma Therapeutics, Inc.
 Semma Therapeutics, Inc. BiotechnologyHealth Technology Semma Therapeutics, Inc. develops transformative therapies for patients who currently depend on insulin injections. It focuses on combining proprietary cells with a state-of-the-art device to provide a true replacement for the missing beta cells in a diabetic patient without immunosuppression. The company was founded by Robert A. Millman, Walter A. Blättler, Felicia Pagliuca, Jeff Imbaro and Douglas A. Melton in 2015 and is headquartered in Cambridge, MA. | Biotechnology | Director/Board Member Director/Board Member Director/Board Member Chief Executive Officer |
Statistieken
Internationaal
| Verenigde Staten | 48 |
| Zwitserland | 2 |
| Japan | 2 |
| Duitsland | 2 |
Sectoraal
| Health Technology | 30 |
| Consumer Services | 7 |
| Finance | 6 |
| Commercial Services | 5 |
| Health Services | 3 |
Operationeel
| Director/Board Member | 332 |
| Corporate Officer/Principal | 124 |
| Private Equity Investor | 72 |
| Independent Dir/Board Member | 70 |
| Founder | 59 |
Sterkste connecties
| Insiders | |
|---|---|
| Ansbert Gadicke | 56 |
| Luke Evnin | 42 |
| Todd Foley | 38 |
| Thomas Ebeling | 33 |
| Anula Kusum Jayasuriya | 31 |
| David Stack | 27 |
| Edward Hurwitz | 27 |
| Mitchell Finer | 26 |
| Briggs Morrison | 26 |
| Jim Scopa | 26 |
| Pablo Cagnoni | 24 |
| Anthony Adam Rosenberg | 23 |
| Patrick Baeuerle | 19 |
| Elizabeth Stoner | 18 |
| Matt Roden | 18 |
- Beurs
- Insiders
- Greg Sieczkiewicz
- Bedrijfsconnecties
